https://orcid.org/0000-0001-8089-067X
References
- Statistikdatabas för operationer i slutenvård: Socialstyrelsen; 2019. [cited 2020 June 26]. Available from: http://www.socialstyrelsen.se. Swedish.
- Sagen E, Hedelin H, Nelzén O, et al. Defining and discriminating responders from non-responders following transurethral resection of the prostate. Scand J Urol. 2018;52(5–6):437–444.
- Sagen E, Namnuan RO, Hedelin H, et al. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system. Scand J Urol. 2019;53(4):240–245.
- Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–249.
- Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–1096.
- Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–140.
- McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803.
- van Exel NJ, Koopmanschap MA, McDonnell J, et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol. 2006;49(1):92–102.
- Statistics Sweden 2020. [cited 2020 June 26]. Available from: http://www.scb.se. Swedish.
- Godartad prostataförstoring med avflödeshinder: en systematisk litteraturöversikt. [Benign prostatic enlargement with obstruction: a systematic literature review]. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2011. Swedish.
- Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–283.
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
- Mitropoulos D, Artibani W, Biyani CS, et al. Validation of the Clavien-dindo grading system in urology by the European Association of Urology Guidelines Ad Hoc Panel. Eur Urol Focus. 2018;4(4):608–613.
- Davis NF, Jack GS, Witjes WP, et al. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. World J Urol. 2019;37(5):873–878.
- Johansen TEB, Istad JA. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scand J Urol. 2007;41:124–131.
- Drake MJ, Williams J, Bijos DA. Voiding dysfunction due to detrusor underactivity: an overview. Nat Rev Urol. 2014;11(8):454–464.
- Kim M, Jeong CW, Oh SJ. Effect of preoperative urodynamic detrusor underactivity on transurethral surgery for benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol. 2018;199(1):237–244.
- Disantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int. 2006;97(5):1007–1016.
- Erman A, Masucci L, Krahn MD, et al. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. BJU Int. 2018;122(5):879–888.
- Ahn HS, Kim SJ, Choi JB, et al. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data. BJU Int. 2019;123(5A):E79–E85.